Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma

Journal of Asthma

Volumn 50, Issue 6, 2013, Pages 687-694

  Özgür, Eylem Sercan ^a   Özge, Cengiz ^a   Ïlvan, Ahmet ^a   Nayci, Sibel Atiş ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Anti IgE; Asthma control test; Omalizumab; Quality of life; Severe asthma

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLUCOCORTICOID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING BETA AGONIST; OMALIZUMAB; SHORT ACTING BETA AGONIST; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY WARD; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE REACTION; LONG TERM CARE; MALE; MEDICAL RECORD; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE; QUESTIONNAIRE; SERUM; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; EMERGENCY SERVICE, HOSPITAL; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84880537802     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.792348     Document Type: Article

References (27)

1. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2011 (accessed date: December 2011). Available from: http://www.ginasthma.org/
2. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH. Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910-917
3. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: A 1-yr prospective study. Eur Respir J 2002; 19:61-67
4. Stirling RG, Chung KF. Severe asthma: Definition and mechanisms. Allergy 2001; 56:825-840
5. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190
6. Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20:73-78
7. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Effectiveness and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to severe) allergic asthma. Allergy 2004; 59:701-708
8. Bavbek S, Aydin O, Kepil Özdemir S, Yilmaz I, Celik GE, Demirel YS, Mungan D, Sin B, Kursun N, Misirligil Z. Therapy with omalizumab in patients with severe persistent allergic asthma: A real life data in Turkey. Tuberk Toraks 2010; 58:425-434
9. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann Intern Med 2011; 154:573-582
10. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103:1633-1642
11. Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, et al. Italian real-life experience of omalizumab. Respir Med 2010: 104:1410-1416
12. Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C. Spanish RegistryOmalizumab therapy in severe asthma: Experience from the Spanish registry-some new approaches. J Asthma 2012; 49:416-422
13. Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: Real-life experience in Israel. J Asthma 2012; 49:78-82
14. Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, Rottbauer W, Kroegel C. Omalizumab in patients with severe asthma: The XCLUSIVE study. Clin Respir J 2012; 6s:215-227
15. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102:71-76
16. Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma 2011; 48:387-392
17. Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience. Pulm Pharmacol Ther. 2012; 25:77-82
18. Storms W, Bowdish MS, Farrar JR. Omalizumab and asthma control in patients with moderrate-to-severe allergic asthma: A 6-year pragmatic data review. Allergy Asthma Proc 2012; 33:172-177
19. Nopp A, Johansson SGO, Adedoyin J, Ankerst J, Palmqvist M, Öman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56-60
20. Menzella F, Facciolongo N, Piro R, Formisano D, Roggeri A, Simonazzi A, Castagnetti C, Carbonelli C, Zucchi L. Clinical and pharmacoeconomic aspects of omalizumab: A 4-year follow-up. Ther Adv Respir Dis 2012; 6:87-95
21. Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma 2012; 49:843-848
22. Global Initiative for Asthma. GINA Global Strategy for Asthma Management and Prevention, 2006. NHI Publications No 02-3659
23. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59-65
24. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115(5):1265-1270
25. Juniper EF, Guyatt GH, Willan A ve ark. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47:81-87
26. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-316
27. Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, QUALITX Study Investigators. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: A Brazilian study (QUALITX). J Asthma 2012; 49:288-293